CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Chief Executive Officer bought 43,000 shares at $2.23 ($95,890)
- 4 Open-market buy President, COO, & CFO bought 9,289 shares at $2.15 ($19,971)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Director acquired 16,000 shares (option exercise)
- 4 Open-market buy Director bought 27,226 shares at an average $3.09 ($84,260)
- 4 Open-market buy Director bought 8,496 shares at an average $3.01 ($25,568)
- 4 Open-market buy Director bought 5,000 shares at $3.09 ($15,450)
- 4 Open-market buy Director bought 4,000 shares at $2.68 ($10,720)
- 4 Open-market buy Director bought 405 shares at $2.70 ($1,094)
- 4 Open-market buy Director bought 7,432 shares at an average $2.66 ($19,749)
- 4 Open-market buy Director bought 10,738 shares at $2.52 ($27,060)
- 4 Open-market buy President, COO, & CFO bought 6,250 shares at $2.40 ($15,000)
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at $2.41 ($60,250)
- 4 Grant or award President, COO, & CFO acquired 1,189 shares (grant or award)
- 4 Open-market buy Director bought 15,009 shares at $3.28 ($49,230)
- 4 Open-market buy Director bought 10,000 shares at $3.63 ($36,300)
Page 3 of 24 · 471 filings